Abdominoplasty After Bariatric Surgery and GLP-1 Receptor Agonists: Independent vs Combined Complication Risks.
Abstract
[BACKGROUND] Rising obesity has surged demand for weight loss interventions and body contouring procedures. The independent and combined effects of prior bariatric surgery (BS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) on abdominoplasty outcomes remain unclear.
[OBJECTIVES] To estimate the independent and combined associations of prior BS and recent GLP-1RA use with 90-day postoperative complications after abdominoplasty.
[METHODS] This retrospective cohort study used TriNetX network data on adults undergoing abdominoplasty (January 2004-June 2025). Patients were grouped into no prior interventions, BS only, recent GLP-1RA use only, and both. Propensity score matching controlled for confounders and 90-day surgical complications were compared.
[RESULTS] Included were 4776 patients with prior BS, 2253 recent GLP-1RA users, and 465 with both. Bariatric surgery increased the risks of hematomas (RR = 1.55; 95% CI 1.11-2.17) and seromas (RR = 1.55; 95% CI 1.19-2.02), lowered hypertrophic scarring (RR = 0.74; 95% CI 0.62-0.87) and systemic infections (RR = 0.78; 95% CI 0.64-0.93). Glucagon-like peptide-1 receptor agonists use heightened hypertrophic scarring risk (RR = 1.79; 95% CI 1.374-2.352), a finding confirmed in a sensitivity analysis against DPP-4 inhibitors (RR = 2.40). Glucagon-like peptide-1 receptor agonist use in BS patients increased wound dehiscence risk (RR = 1.92; 95% CI 1.12-3.38) and constitutional symptoms (RR = 1.69; 95% CI 1.164-2.461).
[CONCLUSIONS] Bariatric surgery is associated with higher hematoma and seroma risks but lower hypertrophic scarring and systemic infections. Glucagon-like peptide-1 receptor agonists are independently associated with hypertrophic scarring risk. When combined, these interventions are associated with significant wound dehiscence and increased constitutional symptoms, underscoring the need for tailored perioperative management and preoperative counseling.
[OBJECTIVES] To estimate the independent and combined associations of prior BS and recent GLP-1RA use with 90-day postoperative complications after abdominoplasty.
[METHODS] This retrospective cohort study used TriNetX network data on adults undergoing abdominoplasty (January 2004-June 2025). Patients were grouped into no prior interventions, BS only, recent GLP-1RA use only, and both. Propensity score matching controlled for confounders and 90-day surgical complications were compared.
[RESULTS] Included were 4776 patients with prior BS, 2253 recent GLP-1RA users, and 465 with both. Bariatric surgery increased the risks of hematomas (RR = 1.55; 95% CI 1.11-2.17) and seromas (RR = 1.55; 95% CI 1.19-2.02), lowered hypertrophic scarring (RR = 0.74; 95% CI 0.62-0.87) and systemic infections (RR = 0.78; 95% CI 0.64-0.93). Glucagon-like peptide-1 receptor agonists use heightened hypertrophic scarring risk (RR = 1.79; 95% CI 1.374-2.352), a finding confirmed in a sensitivity analysis against DPP-4 inhibitors (RR = 2.40). Glucagon-like peptide-1 receptor agonist use in BS patients increased wound dehiscence risk (RR = 1.92; 95% CI 1.12-3.38) and constitutional symptoms (RR = 1.69; 95% CI 1.164-2.461).
[CONCLUSIONS] Bariatric surgery is associated with higher hematoma and seroma risks but lower hypertrophic scarring and systemic infections. Glucagon-like peptide-1 receptor agonists are independently associated with hypertrophic scarring risk. When combined, these interventions are associated with significant wound dehiscence and increased constitutional symptoms, underscoring the need for tailored perioperative management and preoperative counseling.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | abdominoplasty
|
복부성형술 | dict | 4 | |
| 합병증 | wound dehiscence
|
상처열개 | dict | 2 | |
| 합병증 | hematomas
|
scispacy | 1 | ||
| 합병증 | wound
|
scispacy | 1 | ||
| 합병증 | hematoma
|
혈종 | dict | 1 | |
| 합병증 | seroma
|
장액종 | dict | 1 | |
| 약물 | GLP-1RAs
→ glucagon-like peptide-1 receptor agonists
|
C2917359
GLP-1 Receptor Agonist [EPC]
|
scispacy | 1 | |
| 약물 | GLP-1RA
|
scispacy | 1 | ||
| 약물 | 90-day
|
scispacy | 1 | ||
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | [OBJECTIVES]
|
scispacy | 1 | ||
| 약물 | CI 1.19-2.02
|
scispacy | 1 | ||
| 약물 | CI 1.374-2.352
|
scispacy | 1 | ||
| 약물 | CI 1.12-3.38
|
scispacy | 1 | ||
| 약물 | CI 1.164-2.461
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | obesity
|
C0028754
Obesity
|
scispacy | 1 | |
| 질환 | weight loss
|
C1262477
Weight Loss
|
scispacy | 1 | |
| 질환 | hematomas
|
C0018944
Hematoma
|
scispacy | 1 | |
| 질환 | seromas
|
C0262627
Seroma
|
scispacy | 1 | |
| 질환 | systemic infections
|
C0243026
Sepsis
|
scispacy | 1 | |
| 질환 | infections
|
C0851162
Infections of musculoskeletal system
|
scispacy | 1 | |
| 질환 | dehiscence
|
C0149663
Dehiscence
|
scispacy | 1 | |
| 기타 | GLP-1
|
scispacy | 1 | ||
| 기타 | glucagon-like peptide-1 receptor agonists
|
scispacy | 1 | ||
| 기타 | Patients
|
scispacy | 1 | ||
| 기타 | DPP-4
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Case report of a rare soft tissue tuberculosis in a patient undergoing lipoabdominoplasty.
- What is the potential role of the nonopioid suzetrigine in pain management?
- Otoplasty for prominent ear: A systematic review of surgical techniques.
- Combined minimally invasive lymphatic microsurgery and aligned nanofibrillar collagen scaffold for refractory post-traumatic eyelid lymphedema: A case report.
- Tranexamic Acid in Reconstructive Microsurgery: A Systematic Review and Meta-Analysis.